Why AtriCure Is On Investors’ Radar
AtriCure (ATRC) has drawn fresh attention after recent trading, with shares around $56.87 and gains over the past month and past 3 months prompting investors to reassess this medical device specialist.
Recent trading tells a mixed story. AtriCure’s 90 day share price return of 64.65% and 1 year total shareholder return of 60.70% suggest momentum has built over the past year, even though the 5 year total shareholder return is down 20.98%.
Scan other fast moving medical and healthcare opportunities by comparing AtriCure’s recent surge with a curated list of 33 healthcare AI stocks that are also drawing fresh attention.
AtriCure now looks like a stronger business on recent revenue and net income growth, yet the share price has already surged. Are you paying for quality, or overpaying for recent excitement?
Most Popular Narrative: 4% Overvalued
AtriCure’s most followed valuation narrative pegs fair value at about $54.89, slightly below the recent $56.87 close. This focuses attention on how much future execution is already embedded in the price.
The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.
See why 5 investors see AtriCure as 4% overvalued.
Result: Fair Value of $54.89 (OVERVALUED)
Still, the AtriCure story carries real pressure points if pulsed field ablation adoption continues to reduce surgical ablation volumes or if overseas pricing squeezes margins.
Find out about the key risks to this AtriCure narrative.
Next Steps
Mixed signals on AtriCure can spark debate, which is exactly when it helps to move fast, review the full data set yourself, and weigh both the upside potential and the concerns highlighted by the 2 key rewards and 1 important warning sign.
Ready To Find Your Next AtriCure Level Idea?
If AtriCure has your attention, do not stop here. Use the Simply Wall St Screener to uncover other opportunities that fit your style before the crowd spots them.
- Target stability and upside by scanning a 32 resilient stocks with low risk scores that aims to keep downside in check while still offering room to grow.
- Hunt for mispriced quality through a 32 high quality undervalued stocks that highlights financially solid businesses trading below their estimated worth.
- Zero in on financial resilience by reviewing a list of solid balance sheet and fundamentals (25 results) that can help you focus on companies built to withstand shocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com